Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324107 | 0.87 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10323999 | 0.86 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10324261 | 0.83 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10323799 | 0.79 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10323798 | 0.79 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10323747 | 0.78 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10322572 | 0.76 | PIM1 (0.61) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL11308051 | 0.76 | PIM1 (0.68) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10324527 | 0.71 | PIM1 (1.00) | PIM1 | |
| SCHEMBL1759675 | 0.70 | CSNK2A1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604217-B2 | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | SELVITA S.A. (PL) | 2013-12-10 | — | — | US | disclosed |
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2012-07-19 | — | — | US | disclosed |
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2012-07-19 | — | — | US | disclosed |
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2012-07-19 | — | — | US | disclosed |
| WO-2011058139-A1 | A COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA SP. Z O. O. (PL) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184535-A1 | COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | ITK, HASPIN, HCK | PIM1 13/4885CSNK2A2 418/4885CSNK2B 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.